SFCM
CLYM

Seven Fleet Capital Management’s Climb Bio CLYM Stock Holding History

Seven Fleet Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$895K Buy
130,654
+54,254
+71% +$313K 0.28% 65
2025
Q4 		$306K Buy
+76,400
New +$183K 0.21% 58

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Seven Fleet Capital Management's CLYM Position: Q1 2026 in Review

Seven Fleet Capital Management increased its Climb Bio (CLYM) stake by 71% in Q1 2026, buying an estimated $313K and bringing the position to 130,654 shares worth $895K. The position accounts for 0.28% of the portfolio, ranked #65.

Seven Fleet Capital Management first reported a position in CLYM in Q4 2025 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Seven Fleet Capital Management held 130,654 shares of Climb Bio worth $895K as of Q1 2026.
  • Seven Fleet Capital Management bought 54,254 Climb Bio shares in Q1 2026, an estimated $313K.
  • Climb Bio made up 0.28% of Seven Fleet Capital Management's portfolio in Q1 2026, its #65 holding.
  • Seven Fleet Capital Management first reported a position in Climb Bio in Q4 2025 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.